About avenue therapeutics inc - ATXI
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
ATXI At a Glance
Avenue Therapeutics, Inc.
1111 Kane Concourse
Bay Harbor Islands, Florida 33154
| Phone | 1-781-652-4500 | Revenue | 1.40M | |
| Industry | Pharmaceuticals: Major | Net Income | -2,909,000.00 | |
| Sector | Health Technology | Employees | 1 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ATXI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.517 |
| Price to Book Ratio | 1.182 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.221 |
| Enterprise Value to Sales | -0.517 |
| Total Debt to Enterprise Value | N/A |
ATXI Efficiency
| Revenue/Employee | 1,404,000.00 |
| Income Per Employee | -2,909,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.501 |
ATXI Liquidity
| Current Ratio | 2.667 |
| Quick Ratio | 2.667 |
| Cash Ratio | 2.598 |
ATXI Profitability
| Gross Margin | N/A |
| Operating Margin | -234.046 |
| Pretax Margin | -209.90 |
| Net Margin | -207.194 |
| Return on Assets | -103.837 |
| Return on Equity | -125.686 |
| Return on Total Capital | -158.788 |
| Return on Invested Capital | -125.686 |
ATXI Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |